Since July 1, 2026, Medicare has let some beneficiaries buy the weight-loss drugs Wegovy, Zepbound and Foundayo for a flat $50 a month, instead of list prices that often top $1,000. The catch, according to a KFF Health News investigation published Aug. 25 and syndicated by NPR five days later: people with certain FDA-approved medical indications for GLP-1 treatment — including type 2 diabetes, moderate-to-severe obstructive sleep apnea, and a fatty liver disease called MASH (metabolic dysfunction-associated steatohepatitis) — don’t qualify for the $50 price. They’re routed instead to standard Medicare Part D coverage, where the same drugs can cost $200 to $750 or more a month.
La Marca found that out the hard way. He has a body mass index of 42 and severe obstructive sleep apnea. His doctor prescribed Zepbound, which would run him roughly $750 a month at list price, so he applied for the $50 Bridge discount. He was turned down, KFF Health News reported, because his sleep apnea diagnosis is one of the conditions that disqualifies him, even though his BMI alone would otherwise have qualified him. “I’m obese, morbidly obese,” he told the outlet. “I’m livid.”
Key facts
- Program: the Medicare GLP-1 Bridge, a temporary CMS pilot running July 1, 2026 through Dec. 31, 2027
- Price: $50 a month for eligible beneficiaries, versus $200 to $750 or more under standard Part D
- Drugs covered: Wegovy (injection or tablet), Zepbound (KwikPen form only), and Foundayo
- Who qualifies: beneficiaries taking a GLP-1 purely for weight loss, within set BMI tiers
- Who’s excluded: people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH, even if their BMI alone would otherwise qualify
- Eligible population: about 3.8 million Medicare beneficiaries, per KFF
- Excluded population: about 5.9 million enrollees excluded specifically over a disqualifying condition, per KFF Health News
- Projected cost: $3.3 billion to $10 billion over the program’s 18 months, depending on enrollment
Timeline
- April 1, 2026: FDA (Food and Drug Administration) approves Foundayo, Eli Lilly’s oral GLP-1 pill, for weight management
- July 1, 2026: Medicare’s $50 GLP-1 Bridge price takes effect
- Aug. 25, 2026: KFF Health News publishes its investigation
- Five days later: NPR syndicates the investigation
- Dec. 31, 2027: Bridge program is scheduled to end
What the Bridge program actually covers
The program is a temporary CMS pilot called the Medicare GLP-1 Bridge, running from July 1, 2026 through Dec. 31, 2027. It covers three drugs: Novo Nordisk’s Wegovy (as an injection or a tablet), Eli Lilly’s Zepbound in its KwikPen form only, and Foundayo, Eli Lilly’s oral GLP-1 pill that the FDA approved for weight management on April 1, 2026.
To get the $50 price, a Medicare Part D or Medicare Advantage beneficiary with drug coverage generally must be 18 or older, not already receiving a GLP-1 through Part D, and fall into one of three BMI tiers:
- A BMI of 35 or higher, on its own.
- A BMI of 30 to 34, plus heart failure, uncontrolled high blood pressure, or chronic kidney disease at stage 3a or worse.
- A BMI of 27 to 29, plus prediabetes or a history of heart attack, stroke or peripheral artery disease.
The $50 copay doesn’t count toward a beneficiary’s Part D deductible or annual out-of-pocket spending cap.
Why some patients with qualifying conditions pay more
The Bridge price was built for one specific group: people taking a GLP-1 purely for weight loss, with no other Medicare-recognized reason to be on the drug. Anyone who already has what CMS calls a “medically coverable indication” — type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH, a liver disease marked by fat buildup and scarring — is excluded from the discount because they’re considered to already have a coverage path through standard Part D. In practice, that path is far more expensive.
Critics say the design can leave patients with those conditions paying more for the same drugs. “Coverage doesn’t always mean affordable,” Dr. Taylor Lacy, a Kansas primary care physician, told KFF Health News, pointing to the prior-authorization and step-therapy hurdles that can add administrative burden even for patients who do qualify. Dr. Tracy Zvenyach of the Obesity Action Coalition said a short-term discount “is not enough” for a chronic condition requiring ongoing treatment. An AHIP spokesperson, Chris Bond, placed the blame elsewhere, on drugmakers’ pricing.
How many people this affects
KFF’s Medicare policy director, Juliette Cubanski, estimates roughly 3.8 million Medicare beneficiaries are eligible for the $50 price. A separate estimate from KFF Health News puts the number of enrollees excluded specifically because of a qualifying medical condition at about 5.9 million. The 3.8 million figure estimates who could get the discount, while the 5.9 million figure estimates enrollees excluded because of a disqualifying diagnosis; the available reporting does not establish whether the populations overlap. Neither figure is an official CMS enrollment number: CMS has not published its own count of how many beneficiaries have actually signed up.
Cubanski also estimated what the program could cost: about $3.3 billion if a quarter of the roughly 3.8 million eligible beneficiaries enroll for the program’s full 18 months, rising to about $10 billion if three-quarters do.
How Medicare is legally allowed to do this
Federal law generally bars Medicare from paying for a drug used solely for weight loss. CMS is running the Bridge as a temporary demonstration project — testing payment and coverage changes on a limited, time-boxed basis rather than committing to them as a permanent benefit. That approach relies on Section 402 demonstration authority under the Social Security Amendments of 1967, which lets CMS try out payment and coverage changes without making them permanent, according to the trade publication FierceHealthcare. A CMS spokesperson, Timothy Foster, defended the program’s design, saying it “has allowed thousands of eligible beneficiaries to access GLP-1 medications for weight loss at pharmacies nationwide.” CMS also points to processing speed for beneficiaries who do qualify: the agency says most prior-authorization requests for the $50 price are decided within about 12 hours.
The Bridge is separate from a longer-running CMS payment model called BALANCE, aimed at broader GLP-1 access in Medicare and Medicaid. CMS has said it will not move forward with BALANCE’s Medicare Part D component for 2027 because not enough Part D plans agreed to participate. The Bridge is scheduled to run through Dec. 31, 2027.
Not the Humana Medicare Advantage story
Available reporting does not establish a connection between the Bridge program and Humana’s separate decision to cut Medicare Advantage plans for 2027. The stories involve Medicare at the same time but are covered here as separate developments. Humana’s only confirmed role in the GLP-1 Bridge is as the program’s central claims processor, through its work administering a government claims-processing program; that operational role doesn’t connect the Bridge to Humana’s own, separate decisions about which Medicare Advantage plans it will offer in 2027.
What it means for beneficiaries now
The Bridge program is running now and is set to continue through Dec. 31, 2027. Whether it will be extended, replaced or allowed to end after that date has not been announced. For now, the dividing line is simple, if frustrating for patients like La Marca: meet the program’s eligibility rules while using a GLP-1 solely for weight loss, and the price is $50. Qualify because of diabetes, sleep apnea or liver disease, and the price reverts to whatever a beneficiary’s own Part D plan normally charges.
Sources and further reading
- Medicare GLP-1 Bridge: Information for Prescribers
- Weight loss drugs (official Medicare coverage page)
- Fact sheet: Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month
- CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
- FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill